L. Keith Henry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
L. Keith Henry has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Akula Bala Pramod
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, 1301 North Columbia Road, Grand Forks, ND 58202, United States
5 shared publicationsBruce Felts
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, United States
4 shared publicationsDanielle Krout
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, 1301 North Columbia Road, Grand Forks, ND 58202, United States
4 shared publications- Roxanne A. Vaughan
Department of Biomedical Sciences, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58202
4 shared publications James D. Foster
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, 1301 North Columbia Road, Grand Forks, ND 58202, USA
3 shared publicationsJohn R. Lever
Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, 65201, United States; Department of Radiology and Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, United States
3 shared publications
Latest Publications
- 1 February 2019
- Published by Elsevier in Neurochemistry International
- Vol. 123, 34-45
Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter
- 1 February 2019
- Published by Elsevier in Neurochemistry International
- Vol. 123, 34-45
Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter
- 1 January 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 147, 9
Corrigendum to “The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux” [Biochem. Pharmacol. 120 (2016) 46–55]
- 1 January 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 147, 9
Corrigendum to “The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux” [Biochem. Pharmacol. 120 (2016) 46–55]
- 19 July 2017
- Published by Elsevier in Biochemical Pharmacology
- Vol. 142, 204-215
Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs
- 19 July 2017
- Published by Elsevier in Biochemical Pharmacology
- Vol. 142, 204-215
Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs
- 1 January 2017
- Published by Elsevier
- p. 527-535
Interaction of Cocaine Analogue RTI82 With the Dopamine Transporter
- 1 January 2017
- Published by Elsevier
- p. 527-535
Interaction of Cocaine Analogue RTI82 With the Dopamine Transporter
- Open Access
- 28 December 2016
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 8 (5) , 1011-1018
Inhibition of the Serotonin Transporter Is Altered by Metabolites of Selective Serotonin and Norepinephrine Reuptake Inhibitors and Represents a Caution to Acute or Chronic Treatment Paradigms
Previous studies of transgenic mice carrying a single isoleucine to methionine substitution (I172M) in the serotonin transporter (SERT) demonstrated a loss of sensitivity to multiple antidepressants (ADs) at SERT. However, the ability of AD metabolites to antagonize SERT was not assessed. Here we evaluated the selectivity and potency of these metabolites for inhibition of SERT in mouse brain-derived synaptosomes and blood platelets from wild-type (I172 mSERT) and the antidepressant-insensitive mouse M172 mSERT. The metabolites norfluoxetine and desmethylsertraline lost the selectivity demonstrated by the parent compounds for inhibition of wild-type mSERT over M172 mSERT whereas desvenlafaxine and desmethylcitalopram retained selectivity. Furthermore, we show that the metabolite desmethylcitalopram accumulates in the brain and that the metabolites desmethylcitalopram, norfluoxetine and desvenlafaxine inhibit serotonin uptake in wild-type mSERT at potencies similar to their parent compounds suggesting that metabolites may play a role in effects observed following AD administration in wild-type and M172 mice.
- 28 December 2016
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 8 (5) , 1011-1018
Open AccessInhibition of the Serotonin Transporter Is Altered by Metabolites of Selective Serotonin and Norepinephrine Reuptake Inhibitors and Represents a Caution to Acute or Chronic Treatment Paradigms
Previous studies of transgenic mice carrying a single isoleucine to methionine substitution (I172M) in the serotonin transporter (SERT) demonstrated a loss of sensitivity to multiple antidepressants (ADs) at SERT. However, the ability of AD metabolites to antagonize SERT was not assessed. Here we evaluated the selectivity and potency of these metabolites for inhibition of SERT in mouse brain-derived synaptosomes and blood platelets from wild-type (I172 mSERT) and the antidepressant-insensitive mouse M172 mSERT. The metabolites norfluoxetine and desmethylsertraline lost the selectivity demonstrated by the parent compounds for inhibition of wild-type mSERT over M172 mSERT whereas desvenlafaxine and desmethylcitalopram retained selectivity. Furthermore, we show that the metabolite desmethylcitalopram accumulates in the brain and that the metabolites desmethylcitalopram, norfluoxetine and desvenlafaxine inhibit serotonin uptake in wild-type mSERT at potencies similar to their parent compounds suggesting that metabolites may play a role in effects observed following AD administration in wild-type and M172 mice.
- Open Access
- 1 October 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (43) , 29712-29727
Computational and Biochemical Docking of the Irreversible Cocaine Analog RTI 82 Directly Demonstrates Ligand Positioning in the Dopamine Transporter Central Substrate-binding Site
- 1 October 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (43) , 29712-29727
Open AccessComputational and Biochemical Docking of the Irreversible Cocaine Analog RTI 82 Directly Demonstrates Ligand Positioning in the Dopamine Transporter Central Substrate-binding Site
- 1 July 2014
- Published by Elsevier in Neurochemistry International
- Vol. 73, 98-106
Stereoselective inhibition of serotonin transporters by antimalarial compounds
- 1 July 2014
- Published by Elsevier in Neurochemistry International
- Vol. 73, 98-106
Stereoselective inhibition of serotonin transporters by antimalarial compounds
- 1 July 2014
- Published by Elsevier in Neurochemistry International
- Vol. 73, 16-26
Antagonist-induced conformational changes in dopamine transporter extracellular loop two involve residues in a potential salt bridge
- 1 July 2014
- Published by Elsevier in Neurochemistry International
- Vol. 73, 16-26
Antagonist-induced conformational changes in dopamine transporter extracellular loop two involve residues in a potential salt bridge
- Open Access
- 1 January 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (3) , 1825-1840
The Two Na+ Sites in the Human Serotonin Transporter Play Distinct Roles in the Ion Coupling and Electrogenicity of Transport
- 1 January 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (3) , 1825-1840
Open AccessThe Two Na+ Sites in the Human Serotonin Transporter Play Distinct Roles in the Ion Coupling and Electrogenicity of Transport